Search Results - "Wazny, Lori D"

Phosphate-Binder Use in US Dialysis Patients: Prevalence, Costs, Evidence, and Policies by St. Peter, Wendy L., Wazny, Lori D., Weinhandl, Eric D.

“…Medicare costs for phosphate binders for US dialysis patients and patients with chronic kidney disease enrolled in Medicare Part D exceeded $1.5 billion in…”
Get full text

A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs? by Peter, Wendy L. St, Wazny, Lori D., Weinhandl, Eric, Cardone, Katie E., Hudson, Joanna Q.

“…As kidney disease progresses, phosphorus retention also increases, and phosphate binders are used to treat hyperphosphatemia. Clinicians prescribe phosphate…”
Get full text

Canadian Society of Nephrology Commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD by Moist, Louise M., MD, Troyanov, Stéphan, MD, White, Colin T., MD, Wazny, Lori D., PharmD, Wilson, Jo-Anne, PharmD, McFarlane, Phil, MD, Harwood, Lori, MsS, Sood, Manish M., MD, Soroka, Steven D., MD, Bass, Adam, MD, Manns, Braden J., MD

“…The KDIGO (Kidney Disease: Improving Global Outcomes) 2012 clinical practice guideline for anemia management in patients with chronic kidney disease provides…”
Get full text

Sodium thiosulfate, bisphosphonates, and cinacalcet for treatment of calciphylaxis by Raymond, Colette B, Wazny, Lori D

“…The use of sodium thiosulfate, bisphosphonates, and cinacalcet for the treatment of calciphylaxis in adults with chronic kidney disease (CKD) is discussed…”
Get full text

Focused Jurisdictional Scan of Glomerulonephritis Medication Access in Canada: A Program Report by Naipaul, Rohini, Marques, Catherine, Ng, Jenny, Barbour, Sean, Lo, Clifford, Hildebrand, Ainslie M., Siu, Valerie, Prasad, Bhanu, Laurin, Louis-Philippe, Wazny, Lori D., Armstrong, Sean, Tran, Jaclyn, Sheffield, Maneka, Jauhal, Arenn, Hladunewich, Michelle A.

“…Purpose of Program: Glomerulonephritis (GN) is a group of rare kidney diseases that is increasingly being managed with higher cost immunosuppressive (IS)…”
Get full text

The Efficacy and Safety of Megestrol Acetate in Protein-Energy Wasting due to Chronic Kidney Disease: A Systematic Review by Wazny, Lori D., BSc (Pharm), PharmD, Nadurak, Stewart, Orsulak, Cali, BSc (Pharm), CDE, Giles-Smith, Lori, BA (Hons), MLIS, Tangri, Navdeep, MD, PhD, FRCPC

“…Objective To assess the efficacy and safety of oral megestrol acetate (MA) in the management of protein-energy wasting in patients with chronic kidney disease…”
Get full text

Review of the top nephrology studies of 2020-2023 by Wilson, Jo-Anne, Pitman, Jennifer, Marin, Judith, Wazny, Lori D., Battistella, Marisa

Get full text

New models of chronic kidney disease care including pharmacists: improving medication reconciliation and medication management by St. Peter, Wendy L, Wazny, Lori D, Patel, Uptal D

“…PURPOSE OF REVIEWPatients with chronic kidney disease (CKD) are complex, have many medication-related problems (MRPs) and high rates of medication…”
Get full text

Erratum to: A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs? by St. Peter, Wendy L., Wazny, Lori D., Weinhandl, Eric, Cardone, Katie E., Hudson, Joanna Q.

Get full text

Clinical pharmacists and patients with chronic kidney disease by Wazny, Lori D, Raymond, Colette B, Verrelli, Mauro

Get more information

Standards of clinical practice for renal pharmacists by Raymond, Colette B, Wazny, Lori D, Sood, Amy R

Get full text

Cost analysis of an intravenous to subcutaneous epoetin α conversion by Wazny, Lori D, Raymond, Colette B, Sood, Amy R, Eng, Amanda, Verrelli, Mauro

“…A cost analysis of a conversion from intravenous (IV) to subcutaneous (SC) epoetin α in patients receiving chronic in-center hemodialysis (HD). This…”
Get more information

Treatment of leg cramps in patients with chronic kidney disease receiving hemodialysis by Raymond, Colette B, Wazny, Lori D

Get more information

Iron replacement and supplementation in patients with chronic kidney disease by Wazny, Lori D, Raymond, Colette B

“…Interest in optimizing iron management in the treatment of anemia of CKD is growing due to concerns that high doses of ESAs may have deleterious effects and…”
Get more information

Medication adherence in patients with chronic kidney disease by Raymond, Colette B, Wazny, Lori D, Sood, Amy R

Get more information

Hypoglycemics for the treatment of type 2 diabetes in patients with chronic kidney disease: a focus on new agents by Fang, Victor, Wazny, Lori D, Raymond, Colette B

Get more information

Pharmacotherapeutic options for the treatment of depression in patients with chronic kidney disease by Raymond, Colette B, Wazny, Lori D, Honcharik, Patricia L

“…Depressive disorders occur in up to one-third of patients with chronic kidney disease CKD). First-line pharmacologic treatments include selective serotonin…”
Get more information

Evaluation and Management of Drug-Induced Thrombocytopenia in the Acutely Ill Patient by Wazny, Lori D., Ariano, Robert E.

“…The numerous drugs to which the acutely ill are exposed place these patients at a significant risk of developing drug‐induced thrombocytopenia. Such patients…”
Get full text

Treatment of hyperkalemia in patients with chronic kidney disease--a focus on medications by Raymond, Colette B, Sood, Amy R, Wazny, Lori D

Get more information

Sodium thiosulfate, bisphosphonates, and cinacalcet for calciphylaxis by Raymond, Colette B, Wazny, Lori D, Sood, Amy R

Get more information